Table 2. Distribution of KRAS mutations according to the involved hotspot gene sequences and to clinicopathological features.
| mKRAS n (%) | mKRAS ex 2 n (%) | mKRAS ex 3-4 n (%) | mKRAS cod 12 n (%) | mKRAS cod 13 n (%) | |
|---|---|---|---|---|---|
|
Sex | |||||
| F | 52 (46.0) | 44 (44.9) | 8 (47.0) | 35 (46.7) | 9 (42.9) |
| M | 61 (54.0) | 52 (55.1) | 9 (53.0) | 40 (52.3) | 12 (57.1) |
| Subtotal | 113 (100) | 96 (100) | 17 (100) | 75 (100) | 21 (100) |
|
Age (years) | |||||
| Median | 64 | 64 | 65,5 | 64 | 63 |
| Range | 34–84 | 34–84 | 47–76 | 34–84 | 49–74 |
| Subtotal | 101 | 85 | 16 | 66 | 19 |
|
G | |||||
| 1–2 | 57 (73.1) | 48 (73.8) | 9 (69.2) | 36 (72.0) | 12 (80.0) |
| 3–4 | 21 (26.9) | 17 (26.2) | 4 (30.8) | 14 (28.0) | 3 (20.0) |
| Subtotal | 78 (100) | 65 (100) | 13 (100) | 50 (100) | 15 (100) |
|
pT | |||||
| 1–2 | 5 (6.4) | 4 (6.1) | 1 (7.7) | 3 (6.0) | 1 (6.7) |
| 3–4 | 73 (93.6) | 61 (93.9) | 12 (92.3) | 47 (94.0) | 14 (93.3) |
| Subtotal | 78 (100) | 65 (100) | 13 (100) | 50 (100) | 15 (100) |
|
pN | |||||
| 0 | 19 (25.0) | 17 (26.6) | 2 (16.7) | 16 (32.6)a | 1 (6.6)a |
| 1 | 36 (47.4) | 30 (46.8) | 6 (50.0) | 23 (46.9) | 7 (46.7) |
| 2 | 21 (27.6) | 17 (26.6) | 4 (33.3) | 10 (20.4)a | 7 (46.7)a |
| Subtotal | 76 (100) | 64 (100) | 12 (100) | 49 (100) | 15 (100) |
|
Vascular and/or perineural invasion | |||||
| Yes | 52 (75.4) | 44 (75.9) | 8 (72.7) | 32 (74.4) | 12 (80.0) |
| No | 17 (24.6) | 14 (24.1) | 3 (27.3) | 11 (25.6) | 3 (20.0) |
| Subtotal | 69 (100) | 58 (100) | 11 (100) | 43 (100) | 15 (100) |
Abbreviations: m=mutated; ex=exon; cod=codon; F=female; M=male.
a
The percentage of specimens KRAS mutated at the codon 12 is significantly higher in the pN0 than in the pN2 tumours (P<0.05); the opposite occurs in specimens mutated at the codon 13 of the KRAS gene.